ClinicalTrials.gg
CompletedNCT07850518QTX-001Updated Oct 6, 2026

Magnetic Mitohormesis (MM) Treatment in Stroke Rehabilitation.

An interventional study of Quantum Magnetic and Sham Mode MM Device in Rehabilitation Program, Stroke Rehabilitation and Physical Functional Performance, sponsored by QuantumTX Pte Ltd. Completed at 2 sites in Singapore. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by QuantumTX Pte Ltd · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2024, registered Jun 2024).
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Stroke with a site in Singapore — 16 open to participants now, 21 under way, 1 of them phase 3. Stroke · Singapore.

Enrollment
39th of 86
60 · median 51
Started
2024
with 11 others
No phase
58 of 104
13 open now
Registered
87th of 104
by date

Among the 104 studies in Stroke with a site in Singapore, this one is the 39th largest by enrollment of the 86 interventional ones that give a count, is one of 12 that started in 2024, is one of 58 with no phase, and was the 87th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

16 of the 104 studies in Stroke with a site in Singapore are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Stroke with a site in Singapore, or all of them as a file.
02

Study summary

Although sarcopenia is commonly seen in stroke patients with a prevalence rate of 42%, relevant research studies are more in geriatric population rather than in stroke patients. Beside conventional functional physiotherapy, improving blood circulation, improving cellular oxygenation and reducing inflammation by MM therapy is supposed to improve muscle atrophy after stroke, thus enhancing the functional recovery.

The investigators are not investigating the direct effect of MM therapy on muscle mass in the current study, but are looking at the function outcomes and changes in quality of life of patients after MM therapy, which is more relevant to the clinical practice in stroke recovery.

Based on literature review and previous studies, stroke patients might benefit from MM therapy by enhancing the outcomes in functional mobility and measures of quality of life, so the purpose of this study is to investigate if MM treatment could boost the functional recovery and muscle strength on top of the effects from the conventional physiotherapy.

The findings of this study might improve the medical knowledge on how MM therapy could affect clinical function outcome in post-stroke rehabilitation and provide alternative method to enhance motor recovery.

Read the detailed description

In this clinical trial, participants will be exposed to MM fields for 10 minutes per week for a maximum of 12 weeks in addition to standard clinical follow-up.

The route of administration, dosage, and frequency are based on studies done in vitro and in vivo models in mice and in adults. At the Swiss Federal Institute of Technology (ETH) in Zurich, the inventors of the MM device were contracted by the Swiss Agency (Bundesamt für Gesundheit, BAG) to test for the safety of diverse PEMF-delivery devices. The MM device was shown to be non-cytotoxic and non-transforming and produces pulsed magnetic fields at flux densities up to 2 mT peak and consists of a privately designed control unit and coil system. For clinical purposes the MM device will be working at less than this value (1.5 mT). Previous data showed enhancement in muscle with only 10 minutes of non-invasive MM fields exposure per week in mice.

In previous human trials, on healthy individuals following ACL-reconstructive surgery, exposure to MM fields showed muscle metabolic improvement and reduced muscle breakdown (measured effects of MM on serum ceramides, lysophosphatidylcholine, TNNT1 and P3NP), myokine upregulation reflecting improved muscle regeneration (measured effects of MM on Follistatin, IGF1, FGF21, IL-6). This was in response to two 10 minutes MM exposures per week on the operated leg. These findings helped to set up the treatment regime for the MM device to impose myogenic effects, including exposure time per session, number of treatment sessions and duration of treatment.

03

Conditions studied

  • Rehabilitation Program
  • Stroke Rehabilitation
  • Physical Functional Performance

Browse trials for

Keywords

  • Magnetic Mitohormesis (MM) treatment in Stroke Rehabilitation
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult age 30 - 70 years
  2. Diagnosis of stroke(s), with most recent stroke at least 10 weeks prior to study participation
  3. Functional Ambulation Categories (FAC): 2 to 3
  4. Normal cognition with (MOCA) score 21
  5. Intact language skills to comprehend and follow directions as per Investigator's assessment.
  6. Individuals must agree to comply with all study visits and procedures.
  7. Individuals must freely provide consent to study participation.

Exclusion criteria

Exclusion Criteria:

  1. to PEMF therapy, which include electronic implants (e.g., pacemaker, implantable cardioverter defibrillator, cochlear implants)
  2. History of neurological disorder (e.g Seizure, Myasthenia Gravis, Multiple Sclerosis and Myopathies) other than stroke
  3. Pregnant and lactating women
  4. Simultaneously receiving standard care
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Sham comparator
    Sham group

    control group receiving the placebo

    Device: Sham Mode MM Device

  • Active comparator
    Treated Group

    Intervention group receiving MM therapy

    Device: Quantum Magnetic

Interventions

  • DeviceQuantum Magnetic

    The intervention will be held at the stipulated study sites. Participants in the intervention group will be exposed to active pulse electromagnetic field treatment by a tested device. The active pulse electromagnetic field device does not produce heat or cause any sensation to the tissue which allows the participants to be blinded to the treatment.

  • DeviceSham Mode MM Device

    Sham sessions help to maintain participant blinding while eliminating the therapeutic electromagnetic field exposure. The sham device mode reproduces the visual and auditory characteristics of active MM treatment, including display screens, indicator lights, operational sounds, and treatment duration timer. However, no therapeutic electromagnetic field is generated. MM devices can be configured to deliver either active treatment or sham treatment through the use of an RFID card reader. RFID cards are pre-programmed and randomised to correspond to either an active or sham session. When the assigned RFID card is tapped on the device, the corresponding treatment protocol is automatically initiated. Therefore double-blinding of both participants and study team / operators / assessors is possible

06

What researchers measure

Primary outcomes

  1. Safety - Safety profile and Number of participants with treatment-related AEs and SAEs

    To assess safety of MM in subacute stroke patients with moderately affected mobility for functional mobility training, assessed through number of participants with treatment-related adverse events, and safety evaluation of the adverse event (AE) profiles.

    Time frame: 16 weeks

Secondary outcomes

  1. Mobility - 10-Metre Walk Test

    Gait speed assessed by 10-Metre Walk Test, administered by physiotherapist.

    Time frame: From baseline to 16 weeks

  2. Mobility - 5 Times Sit To Stand Test

    Lower limb strength assessed through the 5TSTS administered by a physiotherapist.

    Time frame: From baseline to 16 weeks

  3. Mobility - Timed Up and Go

    Dynamic balance assessed through the TUG administered by a physiotherapist.

    Time frame: From baseline to 16 weeks

  4. Quality of Life - EuroQoL-5D-5L

    EQ-5D-5L is an established tool for assessing the general health status of individuals across a wide array of health conditions and treatments. It measures health outcomes in five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a five-level scale, from no problems (level 1) to extreme problems (level 5), facilitating a comprehensive evaluation of a patient's health-related quality of life. The total score is derived by converting the individual dimension scores into a single summary index value, reflecting the overall health status, with higher scores indicating better health outcomes.

    Time frame: From baseline to 16 weeks

07

Study locations

2 sites
  • Stroke Support Station (S3) - Jurong Point
    Singapore, Singapore 648886, Singapore
  • Stroke Support Station (S3) - Enabling Village
    Singapore, 159053, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Mar 2026, 23 months.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 23 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Sep 30, 2026
StartActual
Mar 20, 2024
Primary completionActual
Mar 1, 2026
CompletionActual
Apr 1, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 2 updates
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: contact details
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850518
Lead sponsor
QuantumTX Pte Ltd
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Mar 20, 2024
Primary completion
Mar 1, 2026
Completion
Apr 1, 2026
Last update
Oct 6, 2026

Study contacts

Gobinathan Chandran
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion